Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) EPS (Basic): 2020-2024

Historic EPS (Basic) for Xeris Biopharma Holdings (XERS) over the last 5 years, with Dec 2024 value amounting to -$0.37.

  • Xeris Biopharma Holdings' EPS (Basic) rose 103.50% to $0.00 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.10, marking a year-over-year increase of 78.15%. This contributed to the annual value of -$0.37 for FY2024, which is 17.78% up from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported EPS (Basic) of -$0.37 as of FY2024, which was up 17.78% from -$0.45 recorded in FY2023.
  • In the past 5 years, Xeris Biopharma Holdings' EPS (Basic) registered a high of -$0.37 during FY2024, and its lowest value of -$2.14 during FY2020.
  • In the last 3 years, Xeris Biopharma Holdings' EPS (Basic) had a median value of -$0.45 in 2023 and averaged -$0.51.
  • Data for Xeris Biopharma Holdings' EPS (Basic) shows a peak YoY skyrocketed of 54.84% (in 2022) over the last 5 years.
  • Over the past 5 years, Xeris Biopharma Holdings' EPS (Basic) (Yearly) stood at -$2.14 in 2020, then grew by 27.57% to -$1.55 in 2021, then surged by 54.84% to -$0.70 in 2022, then surged by 35.71% to -$0.45 in 2023, then rose by 17.78% to -$0.37 in 2024.